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Abstract 26 
Extending licensed drug use for the pediatric population has become an essential part of the drug 27 
development process. Nonetheless ethical concerns limit clinical testing in paediatric populations and 28 
data collected from oral bioavailability and food effect studies in adults are often extrapolated to the 29 
target paediatric (sub)populations. However, based on published information, food effects on drug 30 
absorption in infants may not be adequately evaluated by data collected in adults. In the present study, 31 
a physiologically based pharmacokinetic (PBPK) approach for modeling paracetamol suspension data 32 
collected in adults was proposed with the ultimate aim to investigate whether extrapolation to infants 33 
is substantially affected by the dosing conditions applied to adults. The development of the PBPK 34 
model for adults was performed using GastroPlus™ and, after scaling to infants considering 35 
physiological, anatomical, and drug clearance changes, extrapolation of the different dosing conditions 36 
was performed by applying dosing conditions dependent changes on  paracetamol gastric emptying 37 
process. Successful predictions of observed plasma concentration levels in infants were achieved when 38 
extrapolating from fasted and infant-formula-fed conditions data. Data collected following the 39 
reference meal appeared less useful for simulating paracetamol suspension performance in infants. 40 
The proposed methodology deserves further evaluation using additional high-quality clinical drug data 41 
both in adults and in infants. 42 
Introduction 
 
Extending licensed drug use to the paediatric populations has become an essential part of the drug 
development process to ensure appropriate dosing, efficacy and safety from birth to adulthood (1,2). 
As in adults, the oral route of administration is preferred from birth to adolescence and bioavailability 
studies are required to ensure suitable drug exposure and drug pharmacokinetics (PK) following the 
administration of the age-appropriate dosage form. However, ethical concerns and recruitment issues 
limit clinical testing in these vulnerable age groups more than in adults (3–5).  
 
Physiologically based pharmacokinetic (PBPK) modelling could be a useful tool to drastically decrease 
the need for performing clinical studies in paediatric populations and, therefore, largely eliminate 
relevant concerns. Based on the ability to create PBPK physiologies representative of various human 
developmental stages, PBPK modeling utilization in paediatrics can facilitate drug performance 
predictions prior to testing in a clinical setting and guide drug formulation development (3,5). 
Additionally, to date, PBPK modeling has proven valuable as a tool to gain mechanistic understanding 
of physiological and drug parameters governing oral absorption processes across various paediatric 
age ranges (3,6–9). Interestingly, however, only a few of these studies use multi-compartmental 
representation of the gastro-intestinal (GI) tract, while implementing age-dependent physiological and 
anatomical changes to investigate different dosing and prandial conditions in the target population 
(3,8).  
 
PBPK model development procedure to extrapolate adult data to paediatric populations employs a 
stepwise workflow, beginning by building a validated adult disposition model, followed by the 
development and validation of an adult absorption model, and, ultimately, the extrapolation to the 
paediatric population of interest (10). A recent draft guidance by the US Food and Drug Administration 
(FDA) proposed the use of age-specific meals and quantities for the investigation of populations 
receiving specific meals, e.g., infant formula for infants, without specification of an exact quantity (11). 
Although several studies in adults have employed infant formula or soft foods (e.g., applesauce, 
yoghurt, and fruit puree), the age-adjusted meal quantities simulate drug product administration with 
small amounts of food to facilitate drug formulation dosing and improve acceptability, rather than 
investigate the potential impact of dosing conditions on drug product performance (3,12). A recent 
study in healthy adults revealed reduced early exposure of paracetamol and ibuprofen, after 
administration under conditions simulating the fed state infants and toddlers (1-24 months) compared 
to the administration under conditions simulating the fasted or fed state conditions in adults, as 
suggested by the current regulatory guidelines (9,11,13,14).  
 
This manuscript describes and evaluates a PBPK modeling approach for extrapolation of drug exposure 
form adults to infants with view to the different conditions that can be used to inform the modeling 
process. The first objective was to propose a PBPK approach for modeling the recently collected 
paracetamol paediatric suspension data in adults under fasted and fed state conditions (13,14), and, 
under conditions mimicking dosing to infants (9). The second objective was to investigate if 
extrapolation to infants was substantially affected by the dosing conditions applied to adults. Both 
objectives were achieved by using the PBPK modeling platform GastroPlus™ V9.7.  
Methods  
PK data collection 
Initially, a thorough search at PubMed was performed (completed March 2020) for previously 
published plasma data after intravenous administration (bolus and infusion) and oral administration 
(solution and suspension forms) of paracetamol to adults and paediatrics. Data that had been collected 
after administration of liquids containing excipients influencing the product performance, from an 
unspecified product, after co-administration with drug(s) influencing the GI physiology, and/or by 
employing paediatrics without age stratification were excluded from further consideration. The 
Statelova et al. (2020) study in adults was used as the basis for extrapolation to paediatrics. In addition 
to that study (9), a total of 23 paracetamol PK studies met the search criteria, with 15 studies in adults 
and 8 in paediatrics. From the adult studies, 12 studies reported i.v. paracetamol administration (15–
24) and 2 studies reported oral administration of paracetamol solutions in the fasted state (19,21). 
From the 8 paediatric studies, 5 reported i.v. administration in infants (1 month – 2 years), children 
and adolescents (2 - 18 years) (25,26) and 2 studies reported oral administration in infants (1 month-
2 years) or infants and young children (3-36 months) (27,28). From the 23 studies retrieved from 
literature, plasma concentration-time profiles and respective standard deviations (SD) or standard 
errors of the means (SEM) were digitized using the WebPlotDdigitizer software V4.1 (Ankit Rohatgi, 
2017). Along with the reported plasma levels as a function of time, extracted information also included 
drug dosing conditions, drug products, and demographics of the study population, i.e., number of 
study subjects, age, gender, body height, body weight, and race. For the Statelova et al. study (2020) 
(9), in addition to the published mean plasma concentrations and demographics, individual data were 
also available.  
 
Modeling strategy  
The PBPK model for paracetamol was developed using the GastroPlus™ software platform (V. 9.7, 
Simulations Plus, Lancaster, CA, USA). The model development strategy employed a “middle-out” 
approach (29), whereby model parameterization was guided by clinical observations in humans 
(Figure 1). As part of the applied “learn-confirm-apply” approach (30), the model was built and refined 
using in vivo data sets and, then it was verified using external data sets before applying/extrapolating 
to infants. As a first step, a disposition model for healthy adults was developed and optimized 
according to clinical studies after i.v. drug administration reported in literature (16), followed by 
verification with external clinical datasets not used for the model development (15,18). After gaining 
certainty in the disposition model, oral absorption in adults was described using the Advanced 
Compartmental Absorption and Transit (ACAT™) model within the GastroPlus™ platform for liquid drug 
formulations i.e., solution and suspension. For the paracetamol suspension formulation, different 
prandial and dosing conditions were modeled and relevant parameters were adjusted according to 
data observed in adults (9). The model was scaled to different paediatric age groups for which clinical 
data following intravenous drug dosing was available to confirm the scaling of drug disposition across 
ages. Finally, different dosing and prandial conditions for the administration of the paediatric 
suspension were extrapolated from adults to infants and compared to data observed in this paediatric 
population. 
 
Adult model  
A full PBPK model for adults was established for paracetamol using the data listed in Table I.Human 
physiologies matching to each simulated study demographics (age, body weight, gender, body-mass-
index) were created using the Population Estimates for Age-Related (PEAR) Physiology module within 
GastroPlus™ (6,43,44). Within the PEAR™ physiology module, after selecting the subject 
demographics, blood flows, organ and tissue sizes, as well as tissue composition are adjusted based on 
literature (6,43,44). A default physiology for a healthy American adult 30-year-old male with a body 
weight of 70 kg was used when the simulated study lacked reporting of the demographics. A study 
reported by Clements et al. investigated the i.v. administration of paracetamol at 5 mg/kg and 20 
mg/kg doses covering the range of the typical paracetamol dose-strengths, e.g. 15 mg/kg (16). 
Additionally, the study has been used successfully for building paracetamol PBPK models in literature 
and the study report allowed for reliable extraction of the datapoints (32,33,45). Therefore, based on 
data sets from the study by Clements et al. (16), clearance (CL) and volume of distribution at steady 
state (Vss) were estimated via non-compartmental analysis performed with the PKPlus™ module 
within GastroPlus™ and were used as benchmark values for CL and Vss in healthy adults. Within the 
current modeling development, Vss was derived from the tissue partitioning coefficient values (Kp) for 
perfusion-limited tissues estimated using the Rogers, Roland, Lukacova method (6,38). The predicted 
Vss value was adjusted to match the benchmark value from clinical observations (Table I). The in vivo 
clearance was scaled to in vitro clearance for each enzyme contributing to drug metabolism using a 
retrograde stepwise routine (46) as briefly explained in the following text (exact calculations are 
provided as Supplementary Information). Based on the extensive liver metabolism of the drug and the 
literature reports indicating insignificant paracetamol metabolism in the gut and kidney (16,22,47,48), 
the total clearance was considered to originate from the liver. Hence, the benchmark total 
paracetamol clearance after i.v. administration was used for the estimation of the in vivo unbound 
intrinsic hepatic clearance according to the well-stirred clearance model (49). Based on the hepatic 
metabolism contributions of isoenzymes of the Cytochrome P-450 (CYP), UDP-glucuronosyltransferase 
(UGT), and cytosolic sulfotransferases (SULT) enzyme families, in vivo intrinsic clearance values per 
isoenzyme were calculated (7,16,32). These were further employed to determine in vitro drug-
metabolizing enzyme parameters (Table I) (7,32,33). The disposition model was verified with data from 
reported i.v. studies of paracetamol (External Datasets) that were not utilized for the model 
development.  
 
The ACAT™ model describes the drug dissolution, precipitation, and luminal absorption during drug 
transfer through the nine compartments of the GI-tract within the model, i.e. stomach, duodenum, 
two jejunum, three ileum, and colon compartments (50,51). Each compartment is characterized by a 
physiology-adjusted small-intestinal (SI) length, radius, specific absorption factor (ASF), intraluminal 
fluid volumes and composition, and transit times. Human effective permeability of paracetamol 
(Peff,man) was estimated from the in vitro apparent permeability in Caco-2 cells (Papp,Caco2) employing 
atenolol as a calibrator (7,34,35), Eq. 1.  
 
𝑙𝑜𝑔𝑃𝑒𝑓𝑓,𝑚𝑎𝑛 = 0.6795 × 𝑙𝑜𝑔𝑃𝑎𝑝𝑝, 𝐶𝑎𝑐𝑜2 − 0.3036     Eq. 1 
 
Oral solution data from literature were used as confirmation that the estimated permeability predicted 
paracetamol oral absorption (19,21). The software’s default gastric transit time (GTT) value of 0.1 h 
and 1st order gastric emptying (GE) kinetics were employed for the solution; GTT for 1st order emptying 
kinetics represents the mean gastric transit time value (MGTT) defined as the GE half-life divided by 
the natural logarithm of 2.  
 
Modeling under different dosing conditions 
The exploratory relative bioavailability study by Statelova et al. was performed in healthy adult male 
volunteers and included three study arms to investigate suitable dosing conditions to evaluate the 
performance of paediatric suspensions for administration in infants (1 month-2 years), i.e., 
paracetamol paediatric suspension (Panadol®) (9). The human physiology used for the modeling 
represented the average values of 78 kg, 28 years of age and BMI of 20.23 kg/m2 as reported in the 
study by Statelova et al. (mentioned throughout the text as “population representative”). A single dose 
of 1000 mg was administered on a crossover basis under different dosing conditions. In particular, the 
investigated dosing conditions included administration of the paediatric drug formulation under fasted 
conditions, fed conditions as proposed by current regulatory guidelines for adults (30 min after the 
start of the consumption of the reference meal) (13,14) and conditions mimicking dosing in infants 
where the drug formulation was administered during infant formula consumption, i.e. infant-formula-
fed conditions (9).  
 
Model parameters were adjusted to capture the performance of the paediatric formulation as 
observed in adults, e.g., adjustment of GTT as GE and arrival of paracetamol in the SI were associated 
to paracetamol appearance in the systemic circulation (52).  Due to the multiple-peak phenomenon 
observed for Panadol® under fasted conditions, an empirical modeling strategy was employed 
following “mixed multiple dosing” (MMD) of the suspension to verify that gastric emptying events were 
responsible for the observed profile shape (and not other absorption factors). Multiple GI-physiologies 
were created and applied using alternating rapid (GTT 0.1 h or 0.25 h) and slow GTT (10 h) values 
starting at different timepoints after drugs administration within the performed simulation; the 
multiple GI-physiologies and the different GTT introduced were adjusted (fitted) to simulate the 
observed discontinuous GE of the suspension under fasted conditions. As the goal was to extrapolate 
the model to infants, a compromise was made for a single GE process for fasted state modeling. 
 
For simulations of paracetamol dosing under postprandial conditions, the hepatic blood flow was 
increased by one third of the baseline hepatic blood flow, to mimic the increase splanchnic blood flow 
observed after food consumption (50). By switching the prandial conditions option to “fed conditions”, 
the luminal conditions within the simulated adult physiology were adjusted to the fed state e.g., bile 
salt increased as a function of fat content in the meal, pH increase in the gastric compartment, and 
prolongation of GE. To simulate different prandial conditions within GastroPlus™ V 9.7, in addition to 
a single default fed options for fed conditions applied in previous software versions, the “user-defined 
meal” option allows for flexibility in adapting the GTT as a function of the caloric content and the bile 
salt level adjustment according to the percentage of fat of the selected meal. Simulations were 
performed according to the software-proposed values for the different prandial conditions (referred 
to as “default settings or conditions” simulation throughout the manuscript). Under fed conditions, 
the total caloric content of the meal was 990 kcal with 60 % derived from fats, while under infant-
formula-fed conditions the total caloric content was 520 kcal with 43 % fat content (9). Within the 
present model development, adjustments were undertaken based on in vivo observations for 
parameters that changed as a function of the meal texture and formulation type, e.g., following the 
solid-liquid reference meal the GE process followed 1st order kinetics, although incomplete mixing of 
the suspension led to shorter paracetamol GTT compared to typically reported GE times for similar 
meals, or GE times were prolonged and GE followed zero order kinetics when administered with the 
infant formula (liquid homogeneous) (9). It should be noted that under zero order GE kinetics the GTT 
value to be entered in the software represents  the time for drug gastric emptying to complete .  
 
Moreover, population simulations were performed for the refined settings for the three dosing 
conditions using a virtual population with similar demographics to the study by Statelova et al. (9). 
Under each type of dosing conditions, eight virtual male healthy subjects were generated using the 
PEAR™ module of the modeling platform with age range 21-48 years, body weight range 60-100 kg, 
and BMI range 20-28  kg/m2. Simulation were performed over 10 h. Software default variability was 
employed for all parameters (44), except for the GTT values employed under both postprandial 
conditions, for which no variability could be included based on software limitations.  
 
Paediatric model scaling 
Paediatric physiologies were generated for each paediatric study using the PEAR physiology module 
within the modeling platform (44), i.e., a mean population representative according to the study 
demographics (25,27,28). The generation of virtual subjects (using the PEAR physiology module) 
accounted for maturation and development changes occurring from birth to adolescence, i.e., body 
and tissue sizes, blood parameters, tissue compositions, as well as hepatic CYP-enzyme abundances 
based on data from an exhaustive literature review (6,43,44,53). The microsomal protein per gram 
liver tissue was assumed to be independent of age (44), while age-adjusted scaling factors for enzymes 
of the UGT and SULT families were extracted from literature to scale the adult baseline abundances 
incorporated in the systemic adult parameters within the simulation platform (32,33,53,54). The 
presented scaling approach has been shown to lead to successful modeling of paracetamol metabolism 
across different ages following intravenous drug administration (33). Clinical observations in infants 
and in children and adolescents after i.v. administration were used to verify the present disposition 
model in paediatrics (25).  
 
Oral absorption in infants under different dosing conditions 
Relevant to oral absorption modeling as a function of age, the change of PEAR physiologies accounts 
for developmental changes in the paediatric GI tract within the ACAT™ physiology, such as GI-segments 
length and transit times, and accounts for some of the age-dependent factors that can influence 
paracetamol bioavailability. For the extrapolation to infants and evaluation of the usefulness of the 
three dosing conditions applied in the study by Statelova et al., adjusted parameters from the adult 
paediatric suspension model were scaled to infants and applied to paediatric simulations. In the 
dataset described in (27), 5 infants with a mean age of four months (2 - 6 months) were dosed with a 
target dose of 15 mg/kg Calpol® suspension (dose administered 19.6 mg/kg), while in the dataset 
reported in (28) the paracetamol dose 12.14 mg/kg was given to infants and young children with a 
mean age of ten months (range: 3 - 36 months). As in adults, the performance of the software default 
settings was evaluated during the infant model development, i.e., default settings for the fasted state 
and “user-defined meal” settings using zero and first order kinetics, for a solid-liquid meal and liquid 
homogeneous meal, respectively. As a next step, extrapolated parameters based on the refined adult 
model according to the study by Statelova et al. were used as input for the simulations in infants, with 
detailed description of the extrapolation rationale for the three different conditions described in the 
following paragraph (9). 
 
A recent meta-analysis of GE as a function of age revealed that food type rather than age determined 
GE across ages (55). Therefore, under the assumption that no age dependent GTT changes would occur 
under fasted conditions, the GTT value found to appropriately describe the fasted state was inherited 
directly from the refined adult PBPK model. For the fed conditions and the infant-formula-fed 
conditions, The average paracetamol meal-dependent GE rate was estimated as a function of the type 
(solid-liquid vs. liquid homogeneous meal) and the caloric content of the meal. For this purpose, the 
caloric content of the meal given to adults was divided by the adjusted GTT values employed for the 
fed and infant-formula-fed conditions found to best describe paracetamol appearance in the systemic 
circulation (Eq. 2). Subsequently, fed GTT values for infants were estimated based on the caloric 
content of the recommended formula amounts for the age of interest and the paracetamol meal-
dependent GE (Eq. 3). Different recommended meal calories reported for infant formula were selected 
for the infant group with a mean age four months and for the infant/young children group with a mean 
age ten months, i.e., 140 kcal and 170 kcal, respectively (3).  
 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑃𝑎𝑟𝑎𝑐𝑒𝑡𝑎𝑚𝑜𝑙 𝐺𝑎𝑠𝑡𝑟𝑖𝑐 𝑒𝑚𝑝𝑡𝑦𝑖𝑛𝑔 𝑟𝑎𝑡𝑒𝑎𝑑𝑢𝑙𝑡𝑠,𝑀𝑒𝑎𝑙 =
𝐶𝑎𝑙𝑜𝑟𝑖𝑐 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 (𝑚𝑒𝑎𝑙 𝑏𝑎𝑠𝑒𝑑)
𝑃𝑎𝑟𝑎𝑐𝑒𝑡𝑎𝑚𝑜𝑙 𝐺𝑇𝑇(𝑚𝑒𝑎𝑙 𝑏𝑎𝑠𝑒𝑑)
      Eq. 2 
 
𝑃𝑎𝑟𝑎𝑐𝑒𝑡𝑎𝑚𝑜𝑙 𝐺𝑇𝑇𝑖𝑛𝑓𝑎𝑛𝑡𝑠,𝑚𝑒𝑎𝑙 =  
𝑀𝑒𝑎𝑙 𝑐𝑎𝑙𝑜𝑟𝑖𝑐 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑟𝑒𝑐𝑜𝑚𝑚𝑒𝑛𝑑𝑒𝑑 𝑓𝑜𝑟 𝑎𝑔𝑒 𝑛𝑒𝑒𝑑𝑠
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑃𝑎𝑟𝑎𝑐𝑒𝑡𝑎𝑚𝑜𝑙 𝐺𝑎𝑠𝑡𝑟𝑖𝑐 𝑒𝑚𝑝𝑡𝑦𝑖𝑛𝑔 𝑟𝑎𝑡𝑒𝑎𝑑𝑢𝑙𝑡,𝑀𝑒𝑎𝑙
   Eq. 3 
Where Paracetamol GTT represents the MGTT for a first order GE process (solid-liquid meal) and total 
GTT for a zero order GE process (Infant formula).  
 
In addition to the single simulations, population simulations were performed for the two infant study 
groups, matching the demographics from each study (27,28) under the three dosing conditions 
employing the adjusted GTT values. Software limitations to parameter variability incorporation (GTT) 
is as described for the adult population simulations. 
 
Model performance evaluation  
For population representative and population simulations, (mean) predicted and observed PK 
parameters describing total drug exposure, peak exposure, and time to reach peak exposure (area 
under the plasma concentration vs. time curve (AUC), Cmax, and Tmax, respectively) were compared 
using the predicted vs. observed fold difference (FDpred/obs). The predicted concentration-time profiles 
from population representative simulations and mean predicted plasma concentration-time profiles 
from the population simulations were evaluated by the average fold error (AFE) and the absolute 









     Eq. 4 







    Eq. 5 
 
where n denotes the number of observed sampling points, PREDi and OBSi denote the predicted and 
observed plasma concentration, respectively, at the sampling time point i.  
 
Additionally, for the population simulations, 90 % confidence intervals (CI), and probability contours 
(10 %, 25%, 50 %, 75 %, 90 %, 95 % and 100 %) including 5th and 95th percentiles were evaluated.  
 
AFE values indicate the trend of the simulated data to underpredict (AFE < 1) or overpredict (AFE > 1) 
the observed plasma concentrations, while an AAFE value close to unity signifies the precision of the 
simulations. Predictions resulting in FDpred/obs  and AAFE values less than two are considered adequate 
(56), while stricter evaluation criteria for FDpred/obs   between 0.5-1.5 for and AAFE below 1.5 indicate 
a successful prediction (57).  
 
Parameter sensitivity analysis 
Parameter sensitivity analysis (PSA) was performed according to a one-factor-at-a-time approach to 
understand the uncertainties of the parameters employed within the refined adult oral absorption 
model developed and evaluated in the present investigation regarding drug-related parameters, i.e., 
drug solubility, permeability, particle size radius, as well as physiological parameters, i.e., GTT. The 
investigation was performed with a population representative matching the mean demographic 
parameters of the clinical study by Statelova et al., i.e. 28-year-old male with a 78 kg bodyweight (9). 
Additionally, PSA was run for physiological, drug-dependent, and dosing parameters contributing to 
model uncertainty for infants under fasted, fed, and infant-formula-fed conditions using a physiology 
matching the mean infant representative in Hopkins et al. (27). Physiological parameters included SI 
radius and length, GTT, SITT, and gastric and duodenal pH, while drug-dependent parameters as 
permeability, bile salt solubilization ratio, diffusion coefficient, reference solubility, and particle size 
were investigated as drug-dependent parameters. Finally, the influence of dose strength and dosing 
volume were simulated to explore the influence of trial conditions. Under fed and infant-formula fed 
conditions, PSA was performed additionally regarding the caloric content of the paediatric meal 
administered to the infants (Table SI, supplementary information). The extent to which paracetamol 
PK and PK parameters are influenced by the selected parameter range was evaluated.   
Results 
Adult model performance  
The developed disposition model for adults was able to adequately describe paracetamol disposition 
in the i.v. study used for modeling development when paracetamol was administered at a low dose 
5 mg/kg, i.e., 350 mg (AAFE 1.045) and high dose of 20 mg/kg, i.e., 1400 mg (AAFE 1.080) (Figure 2A 
and 2B, respectively). External datasets used for model verification from two studies (15) simulated 
the observed data acceptably (AAFE 1.131) for predictions at low paracetamol dose of 500 mg 
paracetamol and for predictions at high paracetamol dose of 1000 mg paracetamol (AAFE 1.212), as 
shown in Figures 2C and 2D, respectively. Predicted clearance and Vss values were within observed 
ranges reported in the literature (Table SII, supplementary information). In addition, the disposition 
model was found to simulate all clinical study data following i.v. administration reported in literature 
with reasonable accuracy, as shown in Figure S1 and Table SIII in the supplementary information. The 
effective permeability value for humans scaled from Caco-2 apparent permeability experiments was 
in line with reported permeability ranges (45,58,59). Using the default GastroPlus™ settings for oral 
solution including a GTT of 0.1 h, the developed model achieved satisfactory prediction of paracetamol 
exposure after oral administration of 1000 mg solution in healthy adults in two different clinical studies 
[AAFE 1.088, Figure 3A (19) and AAFE 1.275, Figure 3B (21)]; thus confirming the suitability of the 
permeability value applied (Table SIII, supplementary information).  
 
Modeling under different dosing conditions 
The default settings for fasted and fed conditions utilizing the user-defined meal option for defining 
the meal specific caloric (reference meal 990 kcal and infant formula 520 kcal) and lipid (reference 
meal 60 % and infant formula 43 %) content failed to describe the data observed for the paracetamol 
suspension administered to healthy adults (Figure 4A, 4C, 4E). Consequently, adjustments of the GTT 
values for fasted, fed, and infant-formula-fed conditions were undertaken to match data observed in 
vivo (Figure 4B, 4D, 4F). Results herein are presented for the population representative from the 
Statelova et al. clinical study (9), while results for population simulations including mean profiles and 
their respective 90 % CIs, 5th and 95th percentiles and probability contours are reported in the 
supplementary information in Figure S3 and S3-1 and the mean predicted PK parameters and their 
respective FDpred/obs values are presented in Table SIV. Due to the multiple peak phenomena observed 
under fasted conditions in adults, drug performance was better described when multiple GE events 
were fitted using the MMD dosing available in the software (AFE 0.941 / AAFE 1.052, Figure S2). 
However, for the purposes of extrapolation to infants, a compromise was made for a single GE process 
for fasted state modeling, employing an adjusted GTT of 0.75 h (AAFE 1.200). In the fed state following 
the reference meal, the suspension was emptied faster than the proposed GE times for the reference 
meal, thus requiring an adjustment of the 3.43 h GTT proposed for the meal to 1.5 h. Simulations 
utilizing the adjusted GGT value indicated better predictions compared to predictions using default 
values for GTT, i.e., AAFE 1.145 vs AAFE 1.733, respectively. In line with typical GE kinetics of liquid 
meals (60), under infant-formula-fed conditions, mean plasma concentration-time profiles were well-
described by a zero-order GE. As for the reference meal, GTT adjustments were needed, as default 
parameters underpredicted the delay observed with (AAFE 1.059 vs AAFE 1.873). For the population 
simulations, although the mean predictions successfully matched the observed data, individual 
measured plasma concentrations fell outside the 5th and 95th percentiles for the simulations (Figure 
S3, Supplementary material). This was especially noticeable at early times (Figure S3A and C, 
Supplementary material) for both fed conditions (reference meal and infant formula) and was 
attributed to the limitation of the platform to include any variability for the adjusted GTT values.  
 
Scaling to paediatrics 
Disposition 
Disposition kinetics and clearance employing isoenzymes of the CYP, UGT, and SULT families could 
predict observed paracetamol levels following i.v. administration over 0.25 h at doses of 12.5 mg/kg 
or 19.6 mg/kg (7,32,33). The model scaling was suitable to predict reported concentrations for i.v. 
administration for a population representative of infants (male, mean age 4 months and 4 kg) and of 
a population representative of a mixed children and adolescents group (male, mean age 6 years old 
and 23 kg) (25). Simulations for population representative of infants were performed for a higher dose 
administered at 15 mg/kg (AAFE 1.312, Figure 5A) and a lower dose administered at 12.5 mg/kg (AAFE 
1.081, Figure 5B). On the other hand, simulations for a population representative of the mixed group 
were adequate for a high dose of 15 mg/kg paracetamol (AAFE 1.420, Figure 5C) and a lower dose of 
12.5 mg/kg paracetamol (AAFE 1.187, Figure 5D). 
 
Oral absorption in infants 
Clinical data in infants following oral administration of a liquid paracetamol formulation available from 
two datasets were used for the evaluation of the usefulness of the developed adult model to predict 
paracetamol exposure in infants (27,28). Initially, using the default software settings, simulation of 
paracetamol plasma profiles in infants were performed under the three different dosing conditions. 
Then, for the purpose of extrapolating the fed conditions and the infant-formula-fed conditions to 
infants, adjusted GTT values for infants were calculated based on these values and on caloric needs of 
the population representative of each study (Eq. 2 and Eq. 3), presented in Table II.  
 
All simulations performed for the infant population representative, i.e. 4 month-old infants according 
to (27), are presented in Figure 6. Fasted state simulations employing default software parameters 
(GTT 0.1 h) could not describe early drug exposure, as they underpredicted Tmax (FDpred/obs = 0.60) and 
overpredicted Cmax (FDpred/obs = 1.3), although the overall description of the postabsorptive phase was 
adequate (AAFE 1.185). The fasted conditions extrapolated from the refined adult model (GTT 0.75 h) 
led to a better prediction of the Tmax and slight underprediction of Cmax (FDpred/obs = 0.90), capturing 
both the early and the overall exposure better than the default settings (Figure 6A vs 6B, Table III). 
Following first order GE kinetics of the reference meal (a solid-liquid meal) and a caloric content of 
140 kcal (the caloric content of a meal for a 4-month-old infant), default simulations (GGT = 2.1 h) 
could not successfully describe the data observed (AAFE 1.523, Figure 5C). Calculation of the adjusted 
GTT for infants resulted in a value of 0.21 h (Table II) and although the postabsorptive PK were captured 
(AAFE 1.201) the early exposure was overpredicted (Figure 5D). Under infant-formula-fed conditions 
and following zero order GE kinetics (as in adults), default simulations (GGT = 2.1 h) inaccurately 
described the data observed (AAFE 1.428, Figure 5C). However, when using the adjusted GTT value 
(1.21 h), successful predictions of both early exposure and total exposure were achieved (AAFE 1.215, 
Figure 6F). Mean simulation profiles from the population simulations (n=25, age range 2-6 months) 
corroborated the observations from the single simulations, as shown in Figure S5 (Supplementary 
Information).  
 
Similarly to the simulations for younger infants (27), early exposure was overpredicted when applying 
software default parameters for the fasted state in infants with mean age of 10 months (28) and 
resulted in inaccurate predictions (AAFE 1.442, Figure 7). In contrast, fasted conditions using the 
refined adult model (GTT 0.75 h) matched observed data well (AAFE 1.201, Figure 7B). Following first 
order GE kinetics of the reference meal and caloric content of 170 kcal (the caloric needs of a 10-
month-old infant), simulations employing default value for GTT = 1.89 h resulted in greater absorption 
delay than observed in vivo, as indicated by the AAFE value of 1.87 (Figure 7C). The use of the adjusted 
GTT value for this study (Table II), although seeming to better predict the overall oral paracetamol 
performance compared to the default GTT values (AAFE 1.274 vs AAFE 1.87) led to overprediction of 
Cmax (FDpred/obs = 1.59). Under infant-formula-fed conditions, following zero order GE kinetics, default 
software settings (GTT 1.89 h) and adjusted GTT (1.47 h) underpredicted early exposure, however, 
employment of the adjusted GTT value showed slight improvement in the overall prediction compared 
to the default settings (AAFE 1.40 vs AAFE 1.695, Figure 7F and 7E, respectively). Population 
simulations performed in 25 virtual subjects aged 3-36 months (28) indicated similar findings as the 
observations based on the single simulations with the mean population representative (Figure S7, 
Supplementary Information).  
 
Parameter sensitivity analysis  
PSA was performed for permeability and GTT under the three dosing conditions for the refined model 
for an adult population representative and a 4-month-old infant (9,27). Paracetamol PK showed 
sensitivity regarding the effective human permeability both in infant and adult population 
representatives, especially under fasted conditions (Figures S8 and S9, supplementary information). 
Decrease in paracetamol permeability negatively influenced the fraction of drug absorbed with up to 
10 % compared to the baseline values (data not shown). Increase of GTT in adults and in infants 
resulted in lowered early exposure (Figure 8A), with prolonged Tmax values and Cmax decrease 
(Figure 9 and Figure S10, supplementary information). Furthermore, in infants, increased caloric 
content of the food translated into greater GTT values and led to more pronounced delay in 
paracetamol absorption under adjusted infant-formula-fed conditions when compared to 
extrapolation under adjusted fed conditions (Figure 8B and C and Figure 9 B and D). Overall, 
permeability and GTT changes demonstrated minor impact regarding total drug exposure. 
Additionally, reference solubility, bile salt solubilization ratio, dose volume, as well as the physiological 
parameters investigated demonstrated minor to no sensitivity in infants regardless of the dosing 
conditions applied, i.e. fasted, fed, or infant-formula-fed conditions (Table SI, supplementary 
information).  
Discussion 
Although PBPK modelling has been commonly used for the extrapolation from adults to paediatric 
populations, the usefulness of incorporating adult and/or infant-meal food effect data into PBPK 
modeling to extrapolate to infants has to the best of our knowledge not been reported yet. In this 
study, extrapolation to the infant paediatric subpopulation was performed based on the results of an 
exploratory clinical investigation of the paediatric paracetamol suspension in adults, which was 
designed to elucidate the effects of three different dosing conditions on drug performance, i.e., fasted, 
reference meal-fed and infant-formula-fed conditions (9). The applied PBPK modeling approach 
involved initial refinement of the adult oral absorption model for the different dosing conditions to 
match the in vivo observations reported by the Statelova et al. and these conditions were subsequently 
scaled to simulate paracetamol plasma concentration levels in infants observed after oral 
administration of paracetamol liquid formulations (27,28).  
 
The discrepancy between predictions using default software values and predictions following 
adjustment of GTT values based on observed product performance highlighted the importance of 
model refinement that considered in vivo data collected under age-relevant dosing conditions using 
the commercially available paediatric formulation (Figure 4). Although PBPK modeling confidence with 
respect to oral drug absorption in adults has increased over the years and is considered to be reaching 
maturation for children (3,7,8), some aspects of GE and SI-transfer might not be accurately captured 
by a default approach regardless of age, i.e., discontinuous GE of liquid formulations and/or mixing 
processes between drug formulation and meal (61). In particular, the mismatch between the fasted 
state default prediction and observations for the suspension in adults could be explained by 
discontinuous GE-events resulting in a prolonged GE of the suspension as opposed to a single rapid GE 
event assumed for liquid formulations (9,19,62), i.e., Figure 2. The software platform enabled modeling 
of GE times for the administered drug as a function of different meal caloric contents, assuming 
homogeneous mixing of the drug and ingested meal. However, the default software assumptions of 
homogeneous mixing between drug formulation and the administered meals did not adequately 
reflect paracetamol GE patterns (63,64). Incomplete mixing of the formulation with the solid-liquid 
reference meal would lead to faster paracetamol emptying compared to the meal, as observed in the 
simulations (Figure 4C and 4D). On the other hand, paracetamol suspension mixes better with the 
liquid homogeneous infant formula, leading to paracetamol GE predominantly together with the infant 
formula bolus (9,63). It should be noted that, under both postprandial dosing conditions, 
independently of the meal texture, distinct paracetamol GE processes were not accurately reflected 
by the default ACAT™ model (9,63).  
 
The present infant paracetamol PBPK model was discussed with focus on absorption parameters, as 
the paracetamol disposition and clearance parameters across ages employed in the model have been 
verified and discussed elaborately in previous works (7,32,33). In the present study, successful 
predictions were achieved for 4 month old infants (27) utilizing the refined model based on the in vivo 
performance of paracetamol suspension in adults under fasted conditions or infant-formula-fed 
conditions based on the recommended age-adjusted meal caloric content for the calculation of GTT in 
infants (Eq. 2 and Eq. 3), as shown in Figure 6B and 6F and summarized in Table III. Simulation of the 
administered dose in the population representative of the second available study [mean age of 
10 months, (28)] led to most reasonable predictions using the refined model parameters for fasted 
conditions adjusted according to the study by Statelova et al. (Figure 7B and Table III). Similar 
observations resulted from population simulations for the adjusted dosing conditions (Figures S5 and 
S7, Supplementary information), despite the simulation limitations based on the lack of variability 
included for GTT under both fed conditions. Although the prandial state in both infant studies was not 
reported, the adequacy of the predictions assuming infant-formula-fed state in a 4-month-old infant 
representative can be corroborated by the frequent feedings resulting in non-fasted conditions 
observed in young infants when compared to children and older age-ranges (3,65,66). In comparison, 
another age-dependent oral absorption modeling exercise employing default values for fasted and fed 
state in infants assuming a liquid feed and a semi-solid feed predicted slower absorption compared to 
the predictions in the present investigation (7,27). The delay in predicted absorption might be 
explained by the lack of meal size adjustment as a function of age and/or imperfect capturing of mixing 
events between formulation and meal. Lastly, within the current investigation, the extrapolation based 
on paracetamol GE kinetics after the ingestion of reference meal in adults (9) and the recommended 
age-adjusted meal calories for the estimation of GTT in infants resulted in overprediction of early 
exposure and rapid paracetamol absorption unlike the data observed in infants (27,28), thus appearing 
less suitable for the prediction of oral drug performance in infants.  
In adults the usefulness of paracetamol as a GE marker to elucidate physiological events has been 
widely recognized under fasted state conditions (52,67), however, not after the high-calorie, high-fat 
meal recommended by regulatory agencies for the fed state (52,67). Within the present investigation 
of the fasted state in infants, when comparing the adjusted GTT value extrapolated from adults in the 
fasted state (GTT 0.75 h), the presence of thickening excipients in the paracetamol paediatric 
suspension could be the cause of delayed GE compared to GE of water in paediatrics, as in adults. As 
a note, reported GTT values in neonates who received 5 mL/kg non-caloric liquid and in infants who 
received 20 mL/kg distilled water have been reported to be shorter, 0.17 h and 0.36 h, respectively, 
(68,69), but a  meta analysis across paediatric ages determined a GTT of 0.75 h for aqueous solutions 
in the fasted state (55,70). Regarding the infant-formula-fed conditions, the adjusted paracetamol GTT 
values cannot be compared with reported values from physiological studies in infants following infant 
formula/milk feeds, because the GE kinetics in those studies are not always reported and/or different 
infant formula types, caloric amounts, and formula compositions are used (3,71–74). 
 
As PBPK modeling scaling of oral absorption processes to paediatrics relies on several assumptions 
originating in knowledge gaps regarding physiological development and maturation in paediatrics (6), 
parameters crucial for oral absorption and their impact on drug exposure in infants were investigated 
using a one-factor-at-a-time PSA approach with primary focus on the prandial conditions. Drug 
(formulation) related parameters and most physiological changes in infants appeared to be less 
important for paracetamol exposure (Table SI) (45). As expected for paracetamol, prolonged GE 
translated into absorption delay under fasted conditions (Figure 8 and Figure 9). Under fed conditions, 
GE was investigated as a function of a range of caloric contents of an infant meal. Within the current 
PBPK modeling exercise and extrapolation from adults to infants, recommended infant formula 
volumes and caloric content thereof were used for the estimation of GTT in infants (Eq. 2 and 3) to 
facilitate some standardization. PSA performed to understand the uncertainties underlying the caloric 
content used in this study demonstrated delayed paracetamol absorption in infants for feeds with 
greater caloric contents under infant-formula-fed conditions extrapolated from adults, with less 
pronounced sensitivity within the range of 100-200 kcal feed (Figure 8 and Figure 9).  
 
Paracetamol permeability was another sensitive parameter, the decrease of which led to drug 
absorption delay and slight decrease in total exposure (Figures S6, S7, and S8). Interestingly, the PSA 
under fed conditions induced with infant formula exhibited less sensitivity towards drug permeability 
compared to the fasted conditions regarding Tmax. Drug permeability is generally considered to be an 
age-dependent factor that reaches maturity the age of 2 years, with most of the conclusions originating 
from investigations using dual sugar intestinal permeability tests (3). According to these studies (75–
79), increased permeability has been observed especially during the first days after birth, with 
maturation (closure) of the junctions between epithelial cells ranging between the first days after birth 
up to 15 months of age. Furthermore, age-dependent changes in permeability could be due to ongoing 
morphological development of the shape and size of SI structures, i.e. villi and microvilli, leading to 
surface-area-based decreased absorption capacity at young ages (7). While this parameter might bring 
uncertainty into PBPK models for younger age-groups and should be carefully interpreted, population 
pharmacokinetic investigations suggested that age-related changes of paracetamol absorption rate 
were prominent in the early days after birth, i.e., neonates, who were not within the target group in 
the current investigation (7).  
 
The present study for paracetamol highlighted the importance of informing the PBPK model during 
development with in vivo data employing age-relevant formulation and dosing conditions prior to 
extrapolation as opposed to using default settings to predict paracetamol oral absorption in infants 
(Figure 1). Along with PBPK modeling limitations highlighted and elaborately discussed elsewhere 
(3,7,8), specific limitations of the usefulness and applicability of the results from the present 
methodology include uncertainty regarding compounds whose bioavailability is affected by bile salt 
solubilization, ionizable compounds affected by intraluminal pH changes, drugs with permeability-
limited absorption or transporter-substrates. In the present study, fasted conditions and/or infant-
formula-fed conditions based on the study by Statelova et al. resulted in adequate predictions of 
paracetamol suspension performance in infants (27,28). In contrast, extrapolation following the 
reference meal appeared less useful to predict the observed plasma levels in infants (27,28). Coupling 
in vivo investigations of age-appropriate dosing conditions in adults with PBPK modeling and 
extrapolation to paediatrics provides a practical strategy for paediatric drug formulation testing with 
view to the complex interplay of formulation and age-appropriate meal characteristics.   
Concluding remarks 
Adult clinical data following paracetamol suspension administration under different dosing conditions 
was successfully extrapolated to infants using PBPK modeling. Reasonable simulations were achieved 
applying the refined model for fasted and/or fed state conditions employing a paracetamol meal-
dependent GE based on infant formula. In contrast, default software parameters (GTT) and 
extrapolation to infants using paracetamol GE following the solid-liquid reference meal appeared less 
useful for predicting early exposure. The present investigation extended the utilization of PBPK 
modeling for simulating plasma concentration levels in infant populations in the context of its 
application within the biopharmaceutical investigations of age-appropriate fed conditions. Emphasis 
should be placed on age-dependent meal-drug-formulation interactions, as drug formulations for 
infants can be different than adults’, i.e., suspensions, mini-tablets or multiparticulates and paediatric 
meals have commonly homogeneous texture unlike the reference meal. Our findings support the need 
of paediatric formulation investigations employing foods commonly used in the target paediatric 
subpopulation as recently introduced in regulatory guidelines (11). Furthermore, the present 
investigation indicated that caution should be exercised even when using bioavailability data of BCS 
Class I drugs with non-problematic absorption in adults to extrapolate to infants. Verification of the 
proposed methodology for infant formulation evaluation with broader spectrum of compounds with 
different physicochemical properties is required. Finally, availability of high-quality clinical data in 
infants is of paramount importance for evaluating the biopharmaceutics tools and methodologies and 
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List of figures 
Figure 1 Model development strategy for the evaluation of food effects in infants based on in vivo 
data in adults. Adapted from (3). 
Figure 2 Simulations of paracetamol plasma concentrations following i.v. administration in healthy 
adults. The disposition model was developed according to data observed at a low (A) (5 mg/kg, i.e. 350 
mg) and high dose (B) (20 mg/kg, i.e. 1400 mg) (16). Model verification was performed with clinical 
data sets not used during model development at low 500 mg (C) and high 1000 mg (D) doses (15). 
Symbols denote observed mean data, error bars represent the standard deviation of the observed 
data, and continuous lines represent the simulated plasma concentration-time profile.  
Figure 3 Simulations of paracetamol plasma concentrations following oral administration of 
paracetamol drops solution (A) and solution (B) to healthy adults at a dose of 1000 mg according to 
(19,21). Symbols denote observed mean data, error bars represent the standard deviation of the 
observed data, and discontinuous lines represent the simulated plasma concentration-time profile. 
Figure 4 Predicted plasma concentration-time profiles (continuous purple line) following oral 
administration of pediatric suspension under different dosing conditions: fasted conditions employing 
default GTT value 0.1 h (A) and adjusted GTT value of 0.75 h according to in vivo observations (B); 
Reference-meal-fed conditions employing default calorie-based software estimated GTT of 3.43 h (C) 
and adjusted GTT of 1.5 h according to in vivo observations (D) with first order GE; and infant-formula-
fed conditions simulating infant dosing employing default calorie-based software estimated GTT 2.03 
(E) and adjusted GTT of 4.5 h (F) with zero-order GE. Grey lines denote individual observed data and 
symbols and error bars denote mean observed plasma levels and the standard deviation (n=8 healthy 
male adult volunteers) (9). 
Figure 5 Simulated plasma concentration-time profiles (continuous purple lines) in infants (A and B) 
and in children (C and D) after i.v. administration of paracetamol at doses 15 mg/kg (A and C) or 12.5 
mg/kg (B and D). Observed mean concentrations and standard deviations depicted as black symbols 
and error bars, individual concentrations (n=25 infants and n=56 children and adolescents) are 
depicted with open symbols (25). 
Figure 6 Predicted plasma concentration-time profiles (purple lines) in infants under software default 
fasted conditions, i.e GTT 0.1 h (A) and adjusted fasted conditions, i.e. GTT 0.75 h (B); fed conditions 
employing first order GE (solid-liquid meal) and software default GTT value of 2.1 h (C) or adjusted GTT 
value of 0.21 h (D); infant-formula-fed conditions following zero order GE kinetics (liquid homogeneous 
meals) using software default GTT value of 2.1 h (E) or adjusted GTT value of 1.21 (F). Observed mean 
concentrations and standard deviations depicted as symbols and error bars, individual observed data 
is presented with grey lines (27). 
Figure 7 Predicted plasma concentration-time profiles (purple lines) in infants under software default 
fasted conditions, i.e GTT 0.1 h (A) and adjusted fasted conditions, i.e. GTT 0.75 h (B); fed conditions 
employing first order GE (solid-liquid meal) employing software default GTT value of 1.89 h (C) and 
adjusted GTT value of 0.26 h (D); infant-formula-fed conditions following zero order GE kinetics (liquid 
homogeneous meals) using software default GTT value of 1.89 h (E) and adjusted GTT value of 1.47 (F). 
Observed mean concentrations depicted as symbols (28). 
Figure 8 Simulated plasma concentration-time profile (continuous line) in infant population 
representative under fasted conditions with variation of the GTT between 0.1-1.5 h (A), under fed 
conditions with different caloric intake (70-200 kcal) and adjusted GTT based on the paracetamol 
reference-meal dependent gastric emptying (B), and under infant fed conditions with different caloric 
intake (70-200 kcal) and adjusted GTT extrapolated based on the paracetamol infant-formula-
dependent gastric emptying (C). The color gradient represents increasing GTT values and caloric 
content of the meals from dark to light grey. Observed mean data and standard deviation are 
presented as symbols and error bars (27). 
 
Figure 9 Parameter sensitivity analysis for Cmax and Tmax results in a population representative infant 
(4 months old, (27)) as a function of GTT under adjusted fasted conditions (A and C), or caloric content 
(GTT) influence under adjusted reference-meal-conditions (continuous lines B and D), or caloric 
content influence under adjusted infant-formula-fed conditions (discontinuous lines B and D). Baseline 





















Table I Input parameters used to build the PBPK model for paracetamol 
Parameter Source 
Physicochemical properties  
Molecular weight (g/mol) 151.9 (31–33)  
Compound type Monoprotic weak acid (31–33)  
pKa 9.45 (acidic) (31–33)  
logP a  0.51 (31–33)  
Reference solubility in water (mg/mL) 14 (31) 
Absorption  
Model ACAT GastroPlus™ 
Effective permeability, human (cm/s ×104) 3.897 Calculated based on (7,34,35) 
Dissolution model Johnson GastroPlus™ 
Drug particle radius (µm) 25 Default GastroPlus™ 
Distribution  
Fraction unbound, fu 0.82 (46) 
Blood-plasma ratio 1.09 (47) 
Predicted Vss (L/kg) b 0.86 
 Predicted using the Lukacova, 
Rodgers and Rowland method 
(6,38,39)  
Clearance   
In vivo clearance (L/h) 19.7 (16) 
Enzyme kinetics  




CYP1A2 c 220 30.78 (40)  
CYP2C9 c 660 8.42 (40) 
CYP2C19 c 2000 25.53 (40) 
CYP2D6 c 440 5.62 (40) 
CYP2E1 c 4020 76.97 (40) 
CYP3A4 c 130 57.16 (40) 
UGT1A1 d 5500 6102.67 (41) 
UGT1A9 d 9200 10208.11 (41) 
UGT2B15 d 23000 34045.84 (41) 
SULT1A1 e 2400 1374.06 (42) 
SULT1A3 e  1500 202.89 (42) 
SULT1E1 e  1900 146.22 (42) 
SULT2A1 e  3700 828.35 (42) 
a to achieve the benchmark Vss values observed in vivo, initially logP value of 1.2 was used for the 
calculation of the tissue partitioning coefficients (Kp) (36); measured logP value 0.51 was used thought 
simulations; b Predicted volume of distribution at steady state (Vss); c Cytochrome P450 (CYP) 
isoenzyme, d UDP-glucuronosyltransferase (UGT) isoenzyme, and e cytosolic sulfotransferases (SULT) 
isoenzyme contributing to paracetamol metabolism  
 
  
Table II Paracetamol meal-dependent gastric emptying (GE) based on the gastric transit time (GTT) 
values employed in the refined adult model for the reference meal and the infant formula used for 
inducing fed and infant-formula-fed conditions (9) and adjusted GTT values for paracetamol gastric 











28-years-old male, 78 
kg body weight a 
4-month-old, 4 kg 
body weight b 
10-month-old, 8.6 kg 















1st order GE  




Zero order GE 
520 4.5 1.93 140 1.21 170 1.47 
a mean adult population representative of the study by Statelova et al. (9) 
b mean infant population representative of the study by Hopkins et al. (27) 
c mean infant population representative of the study by Walson et al. (28) 
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Table III Observed and predicted pharmacokinetic parameters in studies performed in infants (27,28). 1 
Simulations in infants were extrapolated based on the refined adult model for different dosing conditions as 2 
described in Statelova et al. (9).  3 
Study Parameter Observed 
Simulated fasted conditions a 
Simulated fed conditions (solid-liquid 
meal) a 
Predicted FDpred/obs  b  
AFE  c / 
AAFE  d 
Predicted FDpred/obs  b  
AFE  c / 
AAFE  d 
Hopkins et al. 
n= 5 subjects 
3 male/2 female  
Dose 19.6 mg/kg 
AUC0-t e 
(ug/mL·h) 








40.21 47.22 1.172 49.24 1.225 
Cmax g 
(ug/mL) 
12.52 11.27 0.900 17.33 1.384 
Tmax h 
(h) 
1.0 1.1 1.1 0.5 0.5 
AUC0-Tmax i 
(ug/mL·h) 
6.88 7.48 1.087 13.51 1.963 
Walson et al. 
n= 13 subjects 
7 male/5 female  












32.76 30.89 0.943 30.99 0.946 
Cmax g 
(ug/mL) 
7.77 7.26 0.934 10.24 1.318 
Tmax h 
(h) 
0.70 1.12 1.60 0.56 0.80 
AUC0-Tmax i 
(ug/mL·h) 
3.62 2.65 0.733 5.05 1.396 
a Conditions simulated based on the refined adult model for different dosing condition as described in 4 
Statelova et al. (9) 5 
b FDpred/obs: Fold difference predicted/observed  6 
c AFE average fold error  7 
d AAFE absolute average fold error 8 
e Area under the plasma concentration-time curve from 0h until the last observed time point (t) AUC0-9 
t (ug/mL·h) 10 
f Area under the plasma concentration-time curve from 0h to infinity AUC0-inf (ug/mL·h) 11 
g Maximum plasma concentration Cmax (ug/mL) 12 
h Time to reach Cmax (h) 13 
i Area under the plasma concentration-time curve from 0h until the mean Tmax observed in the 14 
simulated study AUC0-Tmax (ug/mL·h) 15 
 16 
 17 
  18 
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